[18f]fludeoksiglukoza curium 185 mbq/ml raztopina za injiciranje
[18f]fludeoksiglukoza - raztopina za injiciranje - [18f]fludeoksiglukoza 185 mbq / 1 ml - [18f]fludeoksiglukoza
mibitec 1 mg komplet za pripravo radiofarmaka
gipharma s.r.l. - [tetrakis(2-metoksi-2-metilpropil-1-izocianid)bakrov(i)]tetrafluoroborat - komplet za pripravo radiofarmaka - [tetrakis(2-metoksi-2-metilpropil-1-izocianid)bakrov(i)]tetrafluoroborat 1 mg / 1 viala - [99mtc]tehnecij-sestamibi
mibitec 1 mg komplet za pripravo radiofarmaka
gipharma s.r.l. - [tetrakis(2-metoksi-2-metilpropil-1-izocianid)bakrov(i)]tetrafluoroborat - komplet za pripravo radiofarmaka - [tetrakis(2-metoksi-2-metilpropil-1-izocianid)bakrov(i)]tetrafluoroborat 1 mg / 1 viala - [99mtc]tehnecij-sestamibi
octanine 100 i.e./ml prašek in vehikel za raztopino za injiciranje
prašek in vehikel za raztopino za injiciranje - koagulacijski faktor ix
tekcis 2-50 gbq radionuklidni generator
cis bio international - natrijev[99mtc]tehnecij pertehnetat - radionuklidni generator - natrijev[99mtc]tehnecij pertehnetat 50 gbq / 1 vrečica - [99mtc]tehnecij-pertehnetat
quadramet
cis bio international - samarium (153sm) lexidronam pentasodium - pain; cancer - terapevtski radiofarmacevtiki - quadramet je indiciran za lajšanje bolečine v kosteh pri bolnikih z multiplimi bolečimi osteoblastnimi skeletnimi metastazami, ki zaužijejo tehnecijev [99mtc] označeni bifosfonati pri pregledu kosti. prisotnost osteoblastic zasevki, ki traja do tehnecij [99mtc]-označena biphosphonates mora biti potrjena pred terapijo.
locametz
novartis europharm limited - gozetotide - radionuklidno slikanje - diagnostični radiofarmacevtiki - to zdravilo je samo za diagnostično uporabo. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.
pylclari
curium pet france - piflufolastat (18f) - prostatične neoplazme - diagnostični radiofarmacevtiki - to zdravilo je samo za diagnostično uporabo. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).
octanate 50 i.e./ml prašek in vehikel za raztopino za injiciranje
prašek in vehikel za raztopino za injiciranje - koagulacijski faktor viii
lofarma prick test - lucerna (medicago sativa)
lenis d.o.o. - raztopina za kožni vbodni test - alergijski testi